The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors.
Balbino B, Herviou P, Godon O, Stackowicz J, Goff OR, Iannascoli B, Sterlin D, Brûlé S, Millot GA, Harris FM, Voronina VA, Nadeau KC, Macdonald LE, Murphy AJ, Bruhns P, Reber LL.
Balbino B, et al. Among authors: herviou p.
J Clin Invest. 2020 Mar 2;130(3):1330-1335. doi: 10.1172/JCI129697.
J Clin Invest. 2020.
PMID: 31770111
Free PMC article.